CADTH | Evidence Driven
CADTH | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
Velsipity etrasimod Ulcerative colitis Active
TBC cabotegravir HIV-1 infection, pre-exposure prophylaxis Active
Dificid fidaxomicin Clostridium difficile infection Active
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
N/A Nab-paclitaxel Gastrointestinal cancer Active
Qulipta atogepant Migraine, prevention Active
Vraylar cariprazine Schizophrenia Active
N/A mepolizumab Eosinophilic Granulomatosis with Polyangiitis Active
N/A everolimus Tuberous Sclerosis Complex (TSC) Active
Last Updated : April 28, 2024